Answers are grounded in this paper and cite their sources.
Reports new-onset vitiligo in a patient receiving etanercept for rheumatoid arthritis, suggesting a paradoxical autoimmune response to biologic therapy.
As the usage of biologics for rheumatic diseases increases, such as rheumatoid arthritis and ankylosing spondylitis, various cutaneous adverse events are also being increasingly reported. We experienced a case of development of vitiligo during a TNF-α antagonist therapy in a 22-year-old woman with rheumatoid arthritis. The patient was presented with vitiligo lesions on the dorsum of both hands after 1 month of treatment with etanercept. Vitiligo improved with topical tacrolimus ointment and excimer laser treatment without the discontinuation of etanercept. No clearly defined mechanism for vitiligo induced by TNF-α antagonist exits. However, considering that vitiligo is an autoimmune disorder, the development of this skin lesion in association with the TNF-α antagonist could be explained by a paradoxical induction of the autoimmune process.
No takes yet. Share an insight, caveat, or question.
Song et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: